Inside INdiana Business (press release) INDIANAPOLIS, June 13, 2013 -- Eli Lilly and Company (NYSE: LLY) today announced it has stopped its Phase II study (BACC) for LY2886721, a beta secretase (BACE) inhibitor being investigated as a once daily treatment for its potential to slow the ...
Norwich Evening News ... who is dithering between playing or hanging out with his mates doing nothing much in particular has a more attractive option of playing with his peers, rather than a nasty introduction to the world of being kicked from goalpost to corner flag by a ... and more »
pharmabiz.com ... and other life-threatening TMAs, such as hemolytic uremic syndrome and thrombotic thrombocytopenic purpura, as well as a wide range of additional disorders, including age -related macular degeneration, ischemia-reperfusion injury and transplant ...
The Asian Age In fact, NY SS 13 in many ways turned out to be a fashionable walk in the darkest alley, with many designers showing no inhibition for endorsing black.” Black with a skimpiest appearance of gold, can never go wrong and this season, they are happy to co ... and more »
The Daily Progress And Lorenzoni believes the struggle to attract more male runners spotlights the problem the race avows to attack in the first place: men's reluctance to stay physically fit as they age and the debilitating health problems that result. “Once they're out ... and more »
MiamiHerald.com Recent headlines make it seem that the cure for old age is just around the corner. “Brain Experiment ... A study in Nature last month found that mice injected with a substance that inhibited a molecule known as NF-KB lived longer than normal. Mice ...
Boston Herald A devastating mix of problems, from injuries and age to Terry's own subpar performance, got in the way last season. But the 35-year-old guard, who had arthroscopic ... “It definitely inhibited me a lot,” said Terry. “I was limited. I hadn't really been ... and more »
PR Newswire (press release) INDIANAPOLIS, June 13, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it has stopped its Phase II study (BACC) for LY2886721, a beta secretase (BACE) inhibitor being investigated as a once daily treatment for its potential to ... and more »
Manchester Journal They were able finish almost 90 percent of the work before the winter months inhibited the next steps in their construction, such as paving and striping. "This is a time for the town to say thanks ... to the community," said Hayes. All that is left to ...
Science Daily (press release) ... respectively) and access to treatment (9.0%). Rates and rationale for treatment discontinuation were similar for both tumour necrosis factor inhibitors (TNFi) and non-TNFi biologics. ... In total, 6,209 patients meeting the following criteria 2002 ...
